Recursion Pharmaceuticals acquired Rallybio's joint venture stake.
5 reports, 2 independent
Updated Jul 23
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Recursion Pharmaceuticals acquired Rallybio's joint venture stake.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Rallybio
American biotechnology company
-
Recursion (United States)
company in Salt Lake City, United States
Coverage
Newest first; wire copies grouped- ZacksCan Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? Recursion Pharmaceuticals RXRX faced a significant setback in May 2025 after announcing the discontinuation of three key drug candi
- Insider MonkeyRecursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best small cap AI s
- ZacksRecursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acqui
- ZacksRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program Shares of Recursion Pharmaceuticals RXRX gained 8.7% on Tuesday and continue to gain today. The uptrend was triggered after it a
- Unknown outlet